Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane

Authors:

Abstract
Antiviral drug development against respiratory syncytial virus (RSV) is urgently needed due to the public health significance of the viral infection. Here, we report the anti‐RSV activity of a small molecule, (1S,3R,4R,5R)‐3,4‐ bis {[(E)‐3‐(3,4‐dihydroxyphenyl)prop‐2‐enoyl]oxy}‐l,5‐dihydroxycyclohexane‐1‐ca methyl ester (3,4‐DCQAME) or 3,4‐ O ‐Dicaffeoylquinic acid methyl ester, which can be isolated from several plants of traditional Chinese medicine. We showed for the first time that compound 3,4‐DCQAME potently inhibits RSV entry and infection. In vitro , 3,4‐DCQAME can interact with F(ecto), the ectodomain of RSV fusion (F) protein. In cultured cells, the compound can block the interaction of F(ecto) protein with the cellular membrane and inhibit viral fusion during RSV entry, leading to inhibition of viral gene expression and infection. In RSV‐infected mice that were treated with 3,4‐DCQAME, we observed a reduction of RSV‐induced pathologic changes and substantial inhibition of viral infection and growth in the lung tissues. Our results provide the first direct evidence of the anti‐RSV activity of 3,4‐DCQAME. Furthermore, these results suggest that 3,4‐DCQAME represents a promising lead compound for anti‐RSV therapeutic development.—Tang, W., Li, M., Liu, Y., Liang, N., Yang, Z., Zhao, Y., Wu, S., Lu, S., Li, Y., Liu, F. Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane. FASEB J. 33, 4287–4299 (2019). www.fasebj.org
Funding Information
  • National Natural Science Foundation of China (81473116)
  • Guangdong Provincial Introduction of Innovative Research and Development Team (2014ZT05S136)
  • Science and Technology Planning Project of Guangdong Province (2016A030303011)
  • National Center for Chronic Disease Prevention and Health Promotion (2012ZX10002006-003, 2012ZX10004-207)
  • Key Laboratory of Microbial Resources and Drug Development in Guizhou Province (2009ZX09103-678, 2012ZX09102301-004, 2012ZX09103301-20, 2013ZX09102-031, 2014ZX09509001-001)
  • State Administration of Traditional Chinese Medicine of the People's Republic of China (XTCX2014B01-09)
  • State Key Laboratory of Virology (201705030003)
  • Small Business Innovative Research and Small Business Technology Transfer
  • Open Research Fund of State Key Laboratory of Bioelectronics (2018IOV006, 2013005, 2015KF011)
  • Guangzhou Municipal Science and Technology Program key projects (201707010399)
  • Guangdong Key Laboratory of High Performance and Functional Polymer Materials (2016B 030301004)
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (RO1-AI041927, RO1-AI091536)
  • National Institute of Dental and Craniofacial Research (RO1-DE023935, RO1-DE025462)

This publication has 44 references indexed in Scilit: